


PHARMACEUTICAL 2020

ARDELYX INC. Rank 143 of 362







PHARMACEUTICAL 2020

ARDELYX INC. Rank 143 of 362



The relative strengths and weaknesses of ARDELYX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARDELYX INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 221% points. The greatest weakness of ARDELYX INC. is the variable Research and Development, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is -108%, being 195% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	252,062
Cost of Goods Sold	600
Intangible Assets	0
Liabilities, Current	22,220
Liabilities, Non-Current	2,076
Other Assets	4,284
Other Compr. Net Income	58
Other Expenses	6,029
Other Liabilities	48,831
Other Net Income	2,352
Property and Equipment	3,436
Research and Development	71,677
Revenues	5,281
Selling, General and Administrative Expense	24,267

Output Variable	Value in 1000 USD
Assets	259,782
Liabilities	73,127
Expenses	102,573
Stockholders Equity	186,655
Net Income	-94,940
Comprehensive Net Income	-94,911
Economic Capital Ratio	-108%